M A Lichtman

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3
    Marshall A Lichtman
    University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA Electronic address
    Blood Cells Mol Dis 50:119-30. 2013
  2. ncbi Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma
    Marshall A Lichtman
    University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, New York 14642 0001, USA
    Oncologist 15:1083-101. 2010
  3. ncbi Thrombopoietin in normal and neoplastic stem cell development
    Kenneth Kaushansky
    University of California San Diego Medical Center, San Diego, CA 92103 8811, USA
    Best Pract Res Clin Haematol 22:495-9. 2009
  4. ncbi Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
    Marshall A Lichtman
    University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Oncologist 13:645-54. 2008
  5. ncbi Battling the hematological malignancies: the 200 years' war
    Marshall A Lichtman
    University of Rochester Medical Center, Rochester, New York 14620, USA
    Oncologist 13:126-38. 2008
  6. ncbi The productivity and impact of the Leukemia & Lymphoma Society Scholar Program: the apparent positive effect of peer review
    M A Lichtman
    The Leukemia and Lymphoma Society, White Plains, New York 10605, USA
    Blood Cells Mol Dis 27:1020-7. 2001
  7. ncbi Uncommon phenotypes of acute myelogenous leukemia: basophilic, mast cell, eosinophilic, and myeloid dendritic cell subtypes: a review
    Marshall A Lichtman
    University of Rochester Medical Center, Rochester, NY 14642, USA
    Blood Cells Mol Dis 35:370-83. 2005
  8. ncbi Is it chronic idiopathic myelofibrosis, myelofibrosis with myeloid metaplasia, chronic megakaryocytic-granulocytic myelosis, or chronic megakaryocytic leukemia? Further thoughts on the nosology of the clonal myeloid disorders
    M A Lichtman
    University of Rochester Medical Center, Rochester, NY 14642 0001, USA
    Leukemia 19:1139-41. 2005
  9. ncbi Intellectual property--the dispute between research institutions and voluntary health agencies
    Marshall A Lichtman
    University of Rochester Medical Center, Rochester, New York, USA
    Nat Biotechnol 22:385-6. 2004
  10. ncbi Early gene activation in chronic leukemic B lymphocytes induced toward a plasma cell phenotype
    George B Segel
    Department of Pediatrics, and Unity Health System, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Blood Cells Mol Dis 30:277-87. 2003

Detail Information

Publications15

  1. ncbi A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3
    Marshall A Lichtman
    University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA Electronic address
    Blood Cells Mol Dis 50:119-30. 2013
    ..It is evident to all that new paradigms are needed if acute myelogenous leukemia is to be subdued in most patients with the disease...
  2. ncbi Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma
    Marshall A Lichtman
    University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, New York 14642 0001, USA
    Oncologist 15:1083-101. 2010
    ..Alternatively, obesity may create an environment in which pre-existing clones that are dormant are permitted (selected) to emerge...
  3. ncbi Thrombopoietin in normal and neoplastic stem cell development
    Kenneth Kaushansky
    University of California San Diego Medical Center, San Diego, CA 92103 8811, USA
    Best Pract Res Clin Haematol 22:495-9. 2009
    ..The c-MPL receptor may also play an important role in the development of human myeloproliferative disorders, essential thrombocythemia, myelofibrosis and polycythemia vera, cooperating with the dysregulated Janus kinase JAK2V(617)F...
  4. ncbi Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
    Marshall A Lichtman
    University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Oncologist 13:645-54. 2008
    ....
  5. ncbi Battling the hematological malignancies: the 200 years' war
    Marshall A Lichtman
    University of Rochester Medical Center, Rochester, New York 14620, USA
    Oncologist 13:126-38. 2008
    ..S., that an investment in minimizing the effects of cancer is as important as defending against other threats to the welfare and longevity of their citizens...
  6. ncbi The productivity and impact of the Leukemia & Lymphoma Society Scholar Program: the apparent positive effect of peer review
    M A Lichtman
    The Leukemia and Lymphoma Society, White Plains, New York 10605, USA
    Blood Cells Mol Dis 27:1020-7. 2001
    ....
  7. ncbi Uncommon phenotypes of acute myelogenous leukemia: basophilic, mast cell, eosinophilic, and myeloid dendritic cell subtypes: a review
    Marshall A Lichtman
    University of Rochester Medical Center, Rochester, NY 14642, USA
    Blood Cells Mol Dis 35:370-83. 2005
    ..We discuss the features of these uncommon phenotypes and review the criteria used for their diagnosis...
  8. ncbi Is it chronic idiopathic myelofibrosis, myelofibrosis with myeloid metaplasia, chronic megakaryocytic-granulocytic myelosis, or chronic megakaryocytic leukemia? Further thoughts on the nosology of the clonal myeloid disorders
    M A Lichtman
    University of Rochester Medical Center, Rochester, NY 14642 0001, USA
    Leukemia 19:1139-41. 2005
  9. ncbi Intellectual property--the dispute between research institutions and voluntary health agencies
    Marshall A Lichtman
    University of Rochester Medical Center, Rochester, New York, USA
    Nat Biotechnol 22:385-6. 2004
  10. ncbi Early gene activation in chronic leukemic B lymphocytes induced toward a plasma cell phenotype
    George B Segel
    Department of Pediatrics, and Unity Health System, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Blood Cells Mol Dis 30:277-87. 2003
    ..These findings suggest that the products of these three genes may be central to early steps in the TPA-induced evolution of CLL B cells to a plasmacytic phenotype...
  11. ncbi The paradox of the neutrophil's role in tissue injury
    George B Segel
    Department of Pediatrics, University of Rochester Medical Center, Rochester, New York, USA
    J Leukoc Biol 89:359-72. 2011
    ..In this review, we summarize the evidence for its role as a mediator of tissue injury in these seven conditions, making it or its products potential therapeutic targets...
  12. ncbi Familial (inherited) leukemia, lymphoma, and myeloma: an overview
    George B Segel
    Department of Pediatrics, University of Rochester Medical Center, Rochester, NY 14642, USA
    Blood Cells Mol Dis 32:246-61. 2004
    ....
  13. ncbi Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment
    William Simon
    Department of Biochemistry and Biophysics, University of Rochester School of Medicine, NY 14642, USA
    Blood Cells Mol Dis 37:116-24; discussion 125-7. 2006
    ..The mathematical approach used here permits reexamining the analysis using future data on BCR-ABL inhibitor therapy or allogeneic stem cell transplantation therapy or both...
  14. ncbi Chronic megakaryocytic leukemia, misnamed chronic idiopathic myelofibrosis, has neoplastic not hyperplastic megakaryocytopoiesis
    Marshall A Lichtman
    Blood 110:3085-6. 2007
  15. ncbi The relationship of patient age to the pathobiology of the clonal myeloid diseases
    Marshall A Lichtman
    Department of Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 610, Rochester, NY 14642, USA
    Semin Oncol 31:185-97. 2004
    ..Agents that reverse inherent cellular drug resistance, farnesyltransferase inhibitors, BCL-2 inhibitors, and FLT3 inhibitors are early examples of such approaches...